Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
11.44
-0.03 (-0.26%)
Apr 29, 2025, 10:18 AM EDT - Market open
Nurix Therapeutics Employees
Nurix Therapeutics had 286 employees as of November 30, 2024. The number of employees increased by 2 or 0.70% compared to the previous year.
Employees
286
Change (1Y)
2
Growth (1Y)
0.70%
Revenue / Employee
$197,262
Profits / Employee
-$728,678
Market Cap
872.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NRIX News
- 18 hours ago - Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - GlobeNewsWire
- 3 days ago - Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets - GlobeNewsWire
- 11 days ago - Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha
- 12 days ago - Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions - GlobeNewsWire
- 17 days ago - Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 27 days ago - Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting - GlobeNewsWire